Loading clinical trials...
Loading clinical trials...
An Open-label, Non-randomized Phase 2 Study of Ofatumomab (O) in Combination With ICE (Ifosfamide, Carboplatin, Etoposide)-Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Conditions
Interventions
O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)
Locations
1
Singapore
National Cancer Centre
Singapore, Singapore, Singapore
Start Date
April 1, 2011
Primary Completion Date
December 1, 2015
Completion Date
March 1, 2016
Last Updated
March 23, 2016
NCT05139017
NCT01804686
NCT05755087
NCT04739813
NCT06785818
NCT06043011
Lead Sponsor
National Cancer Centre, Singapore
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions